Showing 1051-1060 of 1484 results for "".
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Eversight Center Awards 2024 Eye & Vision Research Grantshttps://modernod.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/The Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, recently announced it has awarded four grants to investigators at Tufts University in Boston, Massachusetts; Wayne State University in Detroit, Michigan; and University of Michigan in Ann Arbor, Michigan, to advance prom
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republichttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-the-czech-republic/2481212/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribu
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Irelandhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-ireland/2481105/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segme
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Portugalhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-portugal/2481021/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement in Portugal for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the pos
- United Kingdom First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia (Ranibizumab)https://modernod.com/news/united-kingdom-first-to-grant-license-for-tevas-ophthalmology-biosimilar-ongavia-ranibizumab/2480870/Teva Pharmaceutical announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) has granted a licence for Ongavia, a biosimilar to Lucentis (ranibizumab). The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for
- Nicox Granted Patent for NCX 470 in China, Extending Coverage to 2039https://modernod.com/news/nicox-granted-patent-for-ncx-470-in-china-extending-coverage-to-2039/2480655/Nicox SA announced that the Chinese National Intellectual Property Administration (CNIPA) has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039. Wit
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- WHO Grants Emergency Listing to Sinovac’s Coronavirus Vaccinehttps://modernod.com/news/who-grants-emergency-listing-to-sinovacs-coronavirus-vaccine/2479253/The World Health Organization (WHO) issued an emergency-use listing for Sinovac’s inactivated COVID-19 vaccine CoronaVac in adults aged 18 and over, the second such authorization it has granted to a Chinese company, and the seventh listing overall, according to a FirstWord report. Sinopharm